Latest news with #T1D
Medscape
3 days ago
- Health
- Medscape
Next-Generation Obesity Treatments Take Center Stage at ADA
The upcoming American Diabetes Association (ADA) 85th Scientific Sessions will focus on new and evolving weight-loss treatments for people with and without diabetes, along with new biological and technological approaches for managing type 1 diabetes (T1D). Late-breaking symposia will include data from trials of a once-monthly injectable for obesity treatment, a nonpeptide oral GLP-1 receptor agonist (RA), and a medication combining a GLP-1 RA with another drug designed to augment fat loss while preserving lean mass. Other new findings at the meeting include the use of a GLP-1 RA in T1D and the latest data on stem cell-derived islet cell transplantation in T1D. And always, there's much more. The meeting will take place from June 20 to 24, 2025, in Chicago. 'This year again, it will be heavily focused on obesity but more on the next generation of obesity drugs. We're progressing to therapy that may be more amenable to the patient, with less frequent dosing and greater convenience,' Marlon Pragnell, PhD, ADA's vice president of research and science, told Medscape Medical News . A major theme of the meeting, said Conference Planning Committee Chair Mark A. Atkinson, PhD, director of the University of Florida Diabetes Institute, Gainesville, Florida, will be 'after decades of making moderate impacts on both type 1 and type 2 diabetes, we are now in a position where we're moving from baby steps to big leaps, be it through technology, as well as new drugs for type 2 diabetes (T2D) and obesity. There's a very positive evolution here, but now that we have all these new tools, how do we most effectively use them?' And of course, the 'elephant in the room,' Atkinson noted, is the cost of the new approaches and access, another topic that will be addressed in several sessions. 'Cost is also a huge factor. There will be discussions about cost and cost effectiveness.' Late-breaking symposia topics include the following: Once-monthly maridebart cafraglutide (MariTide, Amgen) for the treatment of obesity in people with or without T2D — a 52-week phase 2 study : Although Amgen's top-line results didn't quite meet expectations for weight loss, Pragnell sees the once-monthly dosing as a potential major advantage. 'I think the key thing here is going to be on just the convenience of dosing and that obviously factors into adherence,' he noted. : Although Amgen's top-line results didn't quite meet expectations for weight loss, Pragnell sees the once-monthly dosing as a potential major advantage. 'I think the key thing here is going to be on just the convenience of dosing and that obviously factors into adherence,' he noted. First report of a phase 3 radomized controlled trial of orforglipron, a small nonpeptide GLP-1 RA, as monotherapy in drug-naïve T2D with inadequate glycemic control — the ACHIEVE-1 trial: These will be the full data for Eli Lilly's investigational product, following the release of top-line results in April 2025. The potential advantages here are not just that it would be an oral GLP-1 RA but because it's a nonpeptide small molecule it could be taken regardless of food or liquid intake, it wouldn't require refrigeration, and could potentially be manufactured more cheaply than injected GLP-1 RAs. 'This is actually very exciting,' Pragnell commented. Can we improve the quality of weight loss by augmenting fat mass loss while preserving lean mass? The BELIEVE study of bimagrumab plus semaglutide: The loss of lean muscle along with fat mass with GLP-1 RAs has been an ongoing concern. This phase 2 study in people with obesity but not diabetes examines the effect of combining bimagrumab, a monoclonal antibody that blocks activin type II receptors and stimulates skeletal muscle growth, with the GLP-1 RA semaglutide. Eli Lilly acquired Versanis Bio, which held the rights to bimagrumab, in 2023. The loss of lean muscle along with fat mass with GLP-1 RAs has been an ongoing concern. This phase 2 study in people with obesity but not diabetes examines the effect of combining bimagrumab, a monoclonal antibody that blocks activin type II receptors and stimulates skeletal muscle growth, with the GLP-1 RA semaglutide. Eli Lilly acquired Versanis Bio, which held the rights to bimagrumab, in 2023. Efficacy and safety of CagriSema 2.4 mg/2.4 mg in adults with overweight/obesity — the REDEFINE 1 and REDEFINE 2 clinical trials: Novo Nordisk's CagriSema combines the GLP-1 RA semaglutide with cagrilintide, a dual amylin and calcitonin RA. 'The idea behind the amylin analog is to come to the weight loss at multiple angles. I think it's going to be very interesting. It's clearly a next-generation approach,' Pragnell said. Novo Nordisk's CagriSema combines the GLP-1 RA semaglutide with cagrilintide, a dual amylin and calcitonin RA. 'The idea behind the amylin analog is to come to the weight loss at multiple angles. I think it's going to be very interesting. It's clearly a next-generation approach,' Pragnell said. ADJUnct semaglutide treatment in T1D (ADJUST-T1D) trial outcomes: With obesity increasingly recognized as an issue in T1D, the ADJUnct study examined the impact of adding semaglutide to automated insulin delivery. This symposium will include new trial outcomes. Other late-breaking symposia will cover results of the CATALYST trial of treatment of hypercortisolism in difficult to control T2D, new data from the STRIDE trial of semaglutide in peripheral artery disease, and the full data for the SOUL trial of oral semaglutide (Rybelsus) on cardiovascular and other outcomes in people with T2D at high cardiovascular risk. And there's much more, including results from a trial called PATHWEIGH, focusing on weight management in primary care, updates on inhaled insulin, new data on Vertex's stem cell-derived transplanted islets in T1D, and the use of artificial intelligence in diabetes management. According to Atkinson, 'This year's scientific sessions will showcase cutting-edge advancements in diabetes research through a robust, data-focused program. Whether attending in person or watching on-demand, participants will have the chance to connect with top experts, take part in engaging discussions, and gain critical insights that will help shape the future of diabetes care.' Pregnall and Atkinson had no disclosures.
Health Line
12-06-2025
- Health
- Health Line
How Do You Treat Type 1 Diabetes?
Managing type 1 diabetes means you'll have to take insulin each day. You may also work with a doctor to treat T1D with other medications in addition to insulin, and determine what else may be best for your diabetes care goals. Treating type 1 diabetes (T1D) is not as simple as just taking a particular medication or using a therapy, but it's more of a management puzzle that has many different parts. People with T1D must take insulin because their bodies do not naturally produce it. This is a required and first-line treatment for anyone with this autoimmune condition. Beyond that, people with T1D may also take other medications and use different methods to help manage their blood sugar levels. This is where your healthcare team plays a key role in helping to create a diabetes management plan and how to best treat your T1D based on many factors. Managing type 1 diabetes While the 'treatment' for a chronic condition is often viewed through the lens of medications or other therapies, T1D is one of those that requires constant management and affects how certain medications work. That is why treating T1D goes beyond just insulin and medication use. Diabetes management involves monitoring blood sugar levels, keeping track of what you consume each day, maintaining enough physical activity, managing your mental health, and more. Using insulin People with T1D must take insulin each day. Their bodies don't naturally make insulin, so it must be administered in another way. Many different types of insulin exist, ranging from fast short-acting insulin taken each time you eat or consume carbohydrates to longer-acting insulin that lasts in your body for hours at a time. Whatever type of insulin you take, you administer it through injections with a syringe or prefilled insulin pen. Others may choose to use an insulin pump device to administer their insulin each day. Insulin pens Many different types of insulin pens exist for long-acting and mealtime insulin forms. You may find these differ slightly based on the insulin you're using. Many of the most common insulin pens are disposable. They contain a prefilled cartridge that can be used for a certain number of days, and when the cartridge is empty, the entire pen is thrown away. Some reusable pens are also available, allowing you to replace the insulin cartridge when it's empty. The needles on insulin pens are known as pen needles, and they come in different lengths and thicknesses based on your preferences. Insulin pumps Insulin pumps are wearable devices that people with diabetes use to deliver insulin. They are connected to a spot on your body and continuously give insulin for 2 to 4 days. These devices deliver a programmed amount of insulin through a small tube called a cannula, inserted just under the top layer of your skin. Your doctor will work with you to determine how much insulin you need each day. Insulin pumps can also deliver an insulin bolus, which is an extra dose of insulin in addition to your basal rate. Some pumps may automatically give you boluses based on your higher blood sugar or carbs, but most allow you to enter a manual bolus for the pump to deliver when needed. Historically, insulin pumps were completely manual devices that you had to program for any insulin. In more recent years, advanced technology now available allows for algorithms to calculate and automatically deliver if you use the device with a connected CGM. Off-label medications for type 1 diabetes Other diabetes medications may also be something to discuss with your doctor. These may include Metformin, GLP-1s, or SGLT-2s meds, which aren't cleared by regulators to use with T1D but may be beneficial beyond that labeling. While some research does show the benefit of these medications for T1D, it indicates there may not be a significant blood sugar improvement, and there may be a high risk of increased hypoglycemia, hyperglycemia, and DKA. That is why it's always important to consult a doctor and your diabetes care team to discuss possible pros and cons if you're interested in using an off-label treatment for T1D along with insulin. It's also important to take all medications as prescribed. Metformin Metformin is a type of oral medication that's approved for type 2 diabetes. However, it's now also commonly prescribed by doctors, and some people with T1Ds use them successfully along with their insulin. Since some T1Ds can develop insulin resistance, the insulin they take each day may not work as well as it once did. Metformin may be an option because it helps reduce sugar production in the liver. Your doctor may advise you to take Metformin in addition to insulin, but that could mean they'd have to write an off-label prescription. GLP-1s Glucagon-like peptide-1 receptor (GLP-1) agonists help manage blood sugar levels and reduce hunger and food intake, possibly supporting weight loss along with managing diabetes glucose levels. These may include: Ozempic Wegovy Trulicity Victoza While these are FDA-cleared for those with T2D, some people with type 1 diabetes also choose to use these for the same reasons. The diabetes clinical community, along with T1Ds, has been advocating for the FDA to consider labeling these medications beyond just T2D use, but as of mid-2025, that hasn't yet materialized. SGLT-2 inhibitors Sodium-glucose transport protein 2 (SGLT2) inhibitors are a class of medications that are also known as gliflozins. These prevent glucose from reabsorbing after it's filtered through your kidneys, helping that glucose to leave your body through urine and lowering blood sugar levels. Invokana Jardiance Farxiga Steglatro This 2023 research review found moderate benefits for SGLT-2s in people type 1 diabetes, without an increase in risk or side effects. One specific SGLT-2 called Sotagliflozin (Zynquista) could eventually be used to treat T1D along with insulin. It would work to lower glucose levels by forcing the body to release it in urine and reducing glucose absorption in the gut. This 2019 research review shows the promise of the medication being used for T1D. However, the Food and Drug Administration (FDA) denied Sotagliflozin in both 2019 and 2024 due to some concerns about the medication. However, it is approved by the European Medicines Agency (EMA) and may be reconsidered by the FDA in the future. Consult your diabetes care team Managing and treating type 1 diabetes is a very individualized process that requires working with your healthcare team. They can best help you understand the condition and learn what treatments may be best for your personal diabetes management and health goals. Always consult your care team before making any treatment decisions, including the types and dosages of any medications you take. For people with T1D, this will likely include diabetes specialists, including an endocrinologist, diabetes care and education specialist, and nutritionist or dietitian. Cure research and related treatments While there isn't a T1D cure on the horizon, researchers continue studying ways to prevent this autoimmune condition and reverse it for those who've already been diagnosed. Some of the more promising research avenues currently include: Gene therapy For T1D, gene therapy could involve reprogramming alternative cells, making those reprogrammed cells perform the functions of the original insulin-producing beta cells. But the reprogrammed cells would be different enough from beta cells so that your own immune system wouldn't recognize them as 'new cells' and attack them, which is what happens in the development of T1D. Islet cell transplants This involves transplanting donated or newly created insulin-making islet cells into the body or pancreas of someone with T1D. Islet transplants aren't new and have been an experimental treatment for many years. This requires immunosuppressant drugs, which often have other side effects and are more expensive. Despite the limited promise of this therapy, many challenges exist. In 2023, the FDA approved a first-of-its-kind treatment for a small number of people with T1D who have severe hypoglycemia and struggle to maintain their blood sugars. Known as Lantrida, this is the first pancreatic islet cellular therapy made from deceased donor pancreatic cells. Other ongoing research explores using stem cells to generate new islet cells rather than transplanting them. Functional bionic therapy Largely based on technology that includes insulin pumps and continuous glucose monitors (CGM), these options to treat and manage T1D may be considered a 'functional cure' —something that basically makes life with this type of diabetes minimally burdensome and almost as 'good as being cured' for some people. These may be the evolving technologies, including closed-loop systems that automatically manage insulin and glucose monitoring to keep blood sugars in target range. Various early systems exist and are getting better, and some believe that this could eventually become a standard of care in managing T1D — assuming affordability and access allow for it. The takeaway Insulin is the main and only required treatment for type 1 diabetes. This is needed because people with T1D don't naturally make insulin in their bodies as those without the condition do. Other medications and types of therapy, alongside insulin, may also help people manage their blood sugar levels and diabetes overall. Some of these prescription medications may be considered 'off-label' drugs if your doctor is willing to prescribe them for T1D. Diabetes management means routine blood sugar monitoring, exercise and eating routines, and other aspects, from sleep to mental health.
Yahoo
11-06-2025
- Health
- Yahoo
T1D Exchange Announces 13 Real-World Data Presentations and Posters at the American Diabetes Association (ADA) 85th Scientific Sessions
Studies underscore advances in screening, mental health, health equity, and early intervention in diabetes care. New study examines benefits of continuous glucose monitoring (CGM) in people with type 2 diabetes (T2D) using glucagon-like peptide-1 (GLP-1) therapy. Company strengthens leadership in type 1 diabetes (T1D) and T2D research, with more than 100 publications since 2020. BOSTON, June 11, 2025 /PRNewswire/ -- T1D Exchange, a nonprofit organization that drives meaningful research and improvement in care and outcomes in type 1 diabetes (T1D) and type 2 diabetes (T2D), today announced that new research using real-world data from its Quality Improvement Collaborative (T1DX-QI) and online patient Registry will be shared during 13 presentations at the American Diabetes Association (ADA) 85th Scientific Sessions being held June 20-23, 2025, in Chicago, Illinois. The studies highlight emerging trends and outcomes in diabetes care, including efforts to improve screening for T1D autoantibodies, technology usage, particularly CGMs, and the increased use of GLP-1 therapies by individuals with T2D. Drawing on data from the organization's Registry of more than 20,000 people with T1D, several presentations offer insights into clinical outcomes as well as the broader impact of the disease, including financial strain, mental health challenges, and comorbid conditions. A full list of abstracts being presented is available here. "We are excited to unveil impactful research driven by our growing T1DX-QI network and robust patient Registry," said David Walton, Chief Executive Officer of T1D Exchange. "By uniting over 60 endocrinology clinics, data from 150,000+ individuals with T1D and T2D, and patient-reported outcomes from people with T1D and their caregivers, we're building a collaborative, evidence-driven knowledge base to expand our capabilities, deepen datasets, and generate insights that improve care for people with diabetes." Key studies include an oral presentation exploring equitable strategies to increase CGM adoption by people with T2D, expanding on prior research in T1D: 276-OR, T1D Exchange Multicenter Study—Increasing CGM Adoption in Type 2 Diabetes on Sunday, June 22, 3:15 - 4:15 p.m. CT in Room W185 A-D Additionally, data from 12 studies will be presented during the General Poster Sessions on Saturday, June 21, Sunday, June 22, and Monday, June 23, from 12:30 - 1:30 p.m. CT in Poster Hall F1. "Many of our presentations this year highlight the strength of our engaged T1D community and the value of our growing Registry. Thousands of participants contributed to research that explores the financial, emotional, and clinical realities of living with T1D," said Wendy Wolf, PhD, Vice President of Registry and Outcomes Research at T1D Exchange. "Our Registry not only provides real-world, patient-reported insights, but also serves as a powerful platform for targeted study recruitment, enabling partners to accelerate research that is closely aligned with patient needs. Our Registry has helped recruit for dozens of research studies, including 16 clinical trials – with more than 10,000 Registry participants enrolled in external studies to date." About the T1DX-QI and the T1D Exchange RegistryThe T1D Exchange Quality Improvement Collaborative (T1DX-QI) brings together 60+ endocrinology clinics across the U.S., collectively treating more than 150,000 people living with type 1 and type 2 diabetes, to identify and address gaps in care and accelerate evidence-based, practical solutions. Participating clinics contribute anonymized patient data and insights from their respective clinics, expanding the collective knowledge base and creating a unified data asset to expedite improvements in care for all people living with type 1 and type 2 diabetes. The T1D Exchange Registry is an online longitudinal study that tracks disease progress and gathers information directly from people with type 1 diabetes and caregivers of children with type 1 diabetes. To date, the Registry includes over 20,000 participants in the U.S. These individuals share patient-reported outcomes, including data on disease management. Participants update their information annually, participate in internal research projects, and are connected to external curated research opportunities, including clinical trials. The online Registry is designed to lower barriers to participating in diabetes research, including patient populations often underrepresented in clinical studies. The T1DX-QI and T1D Exchange Registry have contributed to more than 100 publications by T1D Exchange in leading medical journals since 2020. About T1D ExchangeT1D Exchange is a leader in harnessing data to advance diabetes care and outcomes by driving collaborative change. Through real-world evidence and clinical data collection and analysis, its programs provide novel insights that identify gaps in care and refine best practices to improve the lives of those living with diabetes. T1D Exchange supports quality improvement and innovation through its Quality Improvement Collaborative (T1DX-QI), online patient Registry, and data-oriented research services. Through a knowledge-sharing and collaboration-focused approach, T1D Exchange accelerates real-world impact by providing clinicians, researchers, industry partners, and advocates with the resources and services they need for better decision support and population health management. T1D Exchange is a nonprofit organization established in 2010 with ongoing support from The Leona M. and Harry B. Helmsley Charitable Trust. To learn more about T1DX-QI member clinics, click here. For more information on the Registry, visit Media Contact:Suzanne McKeeDirector of Marketing, T1D ExchangePhone: 617-671-0429Email: smcKee@ View original content to download multimedia: SOURCE T1D Exchange
Hans India
10-06-2025
- Health
- Hans India
New AI-powered tool to transform type 1 diabetes diagnosis, treatment
New Delhi: Australian researchers have pioneered a new artificial intelligence (AI)-powered tool to assess the risk of developing type 1 diabetes (T1D). The tool, developed by researchers at Western Sydney University, predicts treatment responses, potentially changing how the disease is diagnosed and managed. The tool utilises an innovative risk score - Dynamic Risk Score (DRS4C) which can classify individuals as having or not having T1D. It is based on microRNAs - small RNA molecules measured from blood -- to help accurately capture the changing risk of T1D. 'T1D risk prediction is timely, with therapies that can delay T1D progression becoming recognised and available. Since early-onset T1D before the age of 10 years is particularly aggressive and linked to up to 16 years of reduced life expectancy, accurately predicting progression gives doctors a powerful tool to intervene sooner,' said Professor Anand Hardikar, lead investigator from the University's School of Medicine and Translational Health Research Institute. In their article published in the journal Nature Medicine, the research analysed molecular data in 5,983 study samples from participants across India, Australia, Canada, Denmark, Hong Kong, New Zealand, and the US, to develop DRS4C. By leveraging AI, the researchers enhanced the risk score, which was validated in 662 other participants. Just an hour after therapy, the risk score predicted which individuals with T1D would remain insulin-free. In addition to T1D risk and drug efficacy prediction, the risk score could potentially discriminate T1D from Type 2 diabetes. Dr. Mugdha Joglekar, lead researcher, from the School of Medicine and Translational Health Research Institute at the University, explained the difference between genetic and dynamic risk markers, adding that genetic testing offered a static view of risk. 'Genetic markers identify lifelong risk, it's like knowing you live in a flood zone, but dynamic risk scores offer a real-time check on the rising water levels; it reflects current risk rather than a lifelong sentence, allowing for timely and adaptive monitoring without stigma,' said Joglekar.
Yahoo
08-06-2025
- Health
- Yahoo
2 Iowa teens attend Type 1 diabetes Children's Congress in Washington, D.C.
DES MOINES, Iowa — Two teenagers from Iowa joined youth from across the world at the Breakthrough T1D Children's Congress in Washington, D.C. this weekend. Every two years, the Children's Congress brings youth from across the world to Washington D.C. to share their Type 1 diabetes stories with Federal lawmakers. This year, the delegates are visiting from June 7 -9 and represent Breakthrough T1D groups across all 50 states, Australia, Canada, Israel, the Netherlands, and the United Kingdom. Greek Food Fair Festival helps keep Church in community The youth will act as delegates who share their stories and the stories of others, while engaging in leadership and advocating for continued research funding. This year, two delegates from Iowa, Elizabeth and Sachin, are sharing their stories. Elizabeth, 17, is from Adel and was diagnosed with T1D at 14 years old, just days before the Super Bowl. She says seeing Noah Grey on the field reminded her that she could do anything. Elizabeth has built a T1D community through sharing tips and tricks, and hopes it helps others feel less alone. Elizabeth enjoys connecting with the community through her job and volunteering, she hopes to open her own business in the future. Sachin, 13, was diagnosed with T1D at 10 and loves everything engineering. Sachin enjoys making fun inventions that bring laughter, and practical ones like a new kind of insulin pump he designed for his recent science fair project. Since his diagnosis, Sachin has attended walks, galas, and summits to support Breakthrough T1D and learn about exciting new technology that could help those living with Type 1 diabetes. Visit the Breakthrough T1D website to learn more about the Children's Congress and the 170 delegates. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
